Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

By K. Rayner, Frederick J. Sheedy, Christine Esau, F. N. Hussain, Ryan E. Temel, Saj Parathath, J. V. van Gils, Alistair J Rayner, Aaron N. Chang, Y. Suárez and 3 more. Journal of Clinical Investigation, 2011

725 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/bfb9c26fa776a96609ee293a1a97c3b91b9e14d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Tiangang Li
2. J. Y. Chiang

In Surgery

1. J. Y. Chiang
2. Tiangang Li

Citations in the corpus

• Development of microRNA therapeutics is coming of age (2014, neutral): “Rayner et al (2011b) showed that treat-ment of normal male African green monkeys by a subcutaneously delivered 2 0 F/MOE-modified antimiR targeting both miR-33a and miR-33b resulted in derepression of hepatic ABCA1 levels and sustained increase in plasma HDL cholesterol over 12 weeks (Rayner et al…”
• Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport (2012, background): “Antagonism of MiR-33 by oligonucleotides raised HDL-C and reduced atherosclerosis in a mouse model, and thus may represent a novel approach to enhancing macrophage cholesterol efflux and raising HDL-C levels in the future (62).”
• Bile Acid Signaling in Metabolic Disease and Drug Therapy (2014, background): “In addition, antagonism of miR-33a was shown to promote regression of atherosclerosis in ldlr mice and nonhuman primates (Rayner et al., 2011).”